HEALTHCARE RESOURCE UTILIZATION WITH IXAZOMIB OR PLACEBO PLUS LENALIDOMIDE-DEXAMETHASONE IN THE RANDOMIZED, DOUBLE-BLIND, PHASE 3 TOURMALINE-MM1 STUDY IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

被引：0
|
作者：
Hari, P. [1 ]
Lin, H. M. [2 ]
Zhu, Y. [2 ]
Berg, D. [2 ]
Richardson, P. [3 ]
Moreau, P. [4 ]
机构：
[1] Med Coll Wisconsin, Milwaukee, WI 53226 USA
[2] Millennium Pharmaceut Inc, Cambridge, MA USA
[3] Dana Farber Canc Inst, Boston, MA 02115 USA
[4] Univ Hosp Hotel Dieu, Nantes, France
来源：
HAEMATOLOGICA | 2017年 / 102卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P735
引用
收藏
页码：297 / 298
页数：2
相关论文
共 50 条
  • [21] Ixazomib Plus Lenalidomide-Dexamethasone (IRd) in Relapsed/Refractory Multiple Myeloma (MM) Patients (Pts) - Effectiveness in Routine Clinical Practice Is Similar to the Efficacy in the Phase 3 Tourmaline-MM1 Trial: A Pooled Analysis from the Insight MM Observational Study and the Czech Registry of Monoclonal Gammopathies (RMG)
    Hajek, Roman
    Terpos, Evangelos
    Lee, Hans C.
    Chari, Ajai
    Costello, Caitlin L.
    Puig, Noemi
    Leleu, Xavier
    Berdeja, Jesus G.
    Davies, Faith E.
    Weisel, Katja
    Usmani, Saad Z.
    Hungria, Vania T. M.
    Boccadoro, Mario
    Rifkin, Robert M.
    Zonder, Jeffrey A.
    Cook, Gordon
    Brozova, Lucie
    Barinova, Magda
    Ren, Kaili
    Cacioppo, Roxanne
    Skacel, Tomas
    Stull, Dawn Marie
    Maisnar, Vladimir
    BLOOD, 2018, 132
  • [22] PATIENT-REPORTED QUALITY OF LIFE WITH IXAZOMIB-LENALIDOMIDE-DEXAMETHASONE (IRD) VS PLACEBO-RD IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS IN THE GLOBAL, PLACEBO-CONTROLLED TOURMALINE-MM1 STUDY
    Leleu, X.
    Masszi, T.
    Bahlis, N. J.
    Viterbo, L.
    Baker, B.
    Gimsing, P.
    Maisnar, V.
    Samoilova, O.
    Rosinol, L.
    Langer, C.
    Song, K.
    Izumi, T.
    Cleeland, C.
    Berg, D.
    Lin, H. M.
    Zhu, Y.
    Skacel, T.
    Jhaveri, M.
    Seal, B.
    Moreau, P.
    Richardson, P. G.
    HAEMATOLOGICA, 2016, 101 : 261 - 261
  • [23] Higher c-MYC Expression Is Associated with Ixazomib-Lenalidomide-Dexamethasone (IRd) Progression-Free Survival (PFS) Benefit Versus Placebo-Rd: Biomarker Analysis of the Phase 3 Tourmaline-MM1 Study in Relapsed/ Refractory Multiple Myeloma (RRMM)
    Di Bacco, Alessandra
    Bahlis, Nizar J.
    Munshi, Nikhil C.
    Avet-Loiseau, Herve
    Masszi, Tamas
    Viterbo, Luisa
    Pour, Ludek
    Ganly, Peter
    Cavo, Michele
    Langer, Christian
    Kumar, Shaji
    Rajkumar, S. Vincent
    Berg, Deborah
    Lin, Jianchang
    Li, Bin
    Badola, Sunita
    Shen, Lei
    Zhang, Jacob
    Wang, Ling
    Esseltine, Dixie-Lee
    Luptakova, Katarina
    de Velde, Helgi van
    Richardson, Paul G.
    Moreau, Philippe
    BLOOD, 2016, 128 (22)
  • [24] Closing the Efficacy and Effectiveness Gap: Outcomes in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated with Ixazomib-Lenalidomide-Dexamethasone (IRd) in Routine Clinical Practice Remain Comparable to the Outcomes Reported in the Phase 3 Tourmaline-MM1 Study
    Hajek, Roman
    Minarik, Jiri
    Straub, Jan
    Pour, Ludek
    Jungova, Alexandra
    Berdeja, Jesus G.
    Boccadoro, Mario
    Brozova, Lucie
    Spencer, Andrew
    van Rhee, Frits
    Vela-Ojeda, Jorge
    Thompson, Michael A.
    Abonour, Rafat
    Chari, Ajai
    Cook, Gordon
    Costello, Caitlin L.
    Davies, Faith E.
    Hungria, Vania T. M.
    Lee, Hans C.
    Leleu, Xavier
    Puig, Noemi
    Rifkin, Robert M.
    Terpos, Evangelos
    Usmani, Saad Z.
    Weisel, Katja C.
    Zonder, Jeffrey A.
    Barinova, Magda
    Kuhn, Matyas
    Silar, Jiri
    Capkova, Lenka
    Galvez, Kenny
    Lu, Jin
    Skacel, Tomas
    Elliott, Jennifer
    Demers, Brittany
    Marie, Dawn
    Ren, Kaili
    Maisnar, Vladimir
    BLOOD, 2019, 134
  • [25] Closing the efficacy and effectiveness gap: Outcomes in Relapsed/Refractory Multiple Myeloma (RRMM) patients (Pts) treated with Ixazomib-lenalidomide-Dexamethasone (IRd) in routine clinical practice remain comparable to the outcomes reported in the phase 3 TOURMALINE-MM1 study
    Weisel, K.
    Hajek, R.
    Minarik, J.
    Straub, J.
    Pour, L.
    Jungova, A.
    Berdeja, J.
    Boccadoro, M.
    Brozova, L.
    Spencer, A.
    Van Rhee, F.
    Vela-Ojeda, J.
    Thompson, M.
    Abonour, R.
    Chari, A.
    Cook, G.
    Costello, C.
    Davies, F.
    Hungria, V
    Lee, H. C.
    Leleu, X.
    Puig, N.
    Rifkin, R.
    Terpos, E.
    Usmani, S.
    Zonder, J.
    Barinova, M.
    Kuhn, M.
    Silar, J.
    Capkova, L.
    Galvez, K.
    Lu, J.
    Skacel, T.
    Elliott, J.
    Demers, B.
    Stull, D. M.
    Ren, K.
    Maisnar, V
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 96 - 97
  • [26] Efficacy and safety of ixazomib plus lenalidomidedexamethasone (IRd) vs placebo-rd in patients (pts) with relapsed/refractory multiple myeloma (RRMM) by cytogenetic risk status in the global phase III Tourmaline-MM1 study.
    Richardson, Paul G.
    Avet-Loiseau, Herve
    Palumbo, Antonio
    Viterbo, Luisa
    Nagler, Arnon
    Ganly, Peter
    Ben Yehuda, Dina
    Miguel, Jesus San
    Rajkumar, S. Vincent
    Pour, Ludek
    Langer, Christian
    Bahlis, Nizar J.
    Pluta, Andrzej
    Masszi, Tamas
    Berg, Deborah
    Lin, Jianchang
    Van De Velde, Helgi
    Esseltine, Dixie-Lee
    di Baccot, Alessandra
    Moreau, Philippe
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [27] CHARACTERIZATION OF THE PHARMACOKINETICS OF IXAZOMIB IN CHINESE PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA IN THE CHINA CONTINUATION OF THE TOURMALINE-MM1 STUDY.
    Hanley, M. J.
    Gupta, N.
    Hou, J.
    Xu, Y.
    Jin, J.
    Chen, X.
    Wang, B.
    Wang, H.
    van de Velde, H.
    Venkatakrishnan, K.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 101 (S1) : S31 - S31
  • [28] Ixazomib plus Lenalidomide-Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients: A Pooled Analysis from the INSIGHT MM Observational Study and the Czech Registry of Monoclonal Gammopathies
    Cook, G.
    Hajek, R.
    Terpos, E.
    Lee, H. C.
    Chari, A.
    Costello, C. L.
    Puig, N.
    Leleu, X.
    Berdeja, J. G.
    Davies, F. E.
    Weisel, K. C.
    Usmani, S. Z.
    Hungria, V. T. M.
    Boccadoro, M.
    Rifkin, R. M.
    Zonder, J. A.
    Brozova, L.
    Barinova, M.
    Ren, K.
    Cacioppo, R.
    Skacel, T.
    Stull, D. M.
    Maisnar, V.
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 185 : 16 - 17
  • [29] Ixazomib Plus Lenalidomide-Dexamethasone (IRd) vs. Placebo-Rd for Newly Diagnosed Multiple Myeloma (NDMM) Patients Not Eligible for Autologous Stem Cell Transplant: The Double-Blind, Placebo-Controlled, Phase 3 TOURMALINE-MM2 Trial
    Facon, Thierry
    Venner, Christopher P.
    Bahlis, Nizar J.
    Attal, Michel
    Offner, Fritz
    White, Darrell J.
    Karlin, Lionel
    Benboubker, Lotfi
    Rigaudeau, Sophie
    Rodon, Philippe
    Voog, Eric
    Yoon, Sung-Soo
    Suzuki, Kenshi
    Shibayama, Hirohiko
    Zhang, Xiaoquan
    Yung, Godwin
    Rifkin, Robert M.
    Moreau, Philippe
    Lonial, Sagar
    Kumar, Shaji K.
    Richardson, Paul G.
    Rajkumar, S. Vincent
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S307 - S308
  • [30] Overall Survival (OS) Benefit of Oral Ixazomib in Combination with Lenalidomide and Dexamethasone (IRd) Vs Lenalidomide and Dexamethasone (Rd) in Asian Patients (pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM): Pooled-Analysis from the Tourmaline-MM1 and the China Continuation Studies
    Fu, Weijun
    Lu, Jin
    Jin, Jie
    Xu, Yan
    Wu, Depei
    Zhou, Dao-bin
    Ke, Xiaoyan
    Du, Xin
    Chen, Xiequn
    Chng, Wee Joo
    Kim, Kihyun
    Li, Junmin
    Lee, Jae Hoon
    Liu, Jing
    Goh, Yeow Tee
    Wu, Kwang-Wei
    Wang, Hui
    Liu, Guohui
    Skacel, Tomas
    Wan, Hui
    Berg, Deborah
    BLOOD, 2018, 132
12345